Basel, Switzerland, October 11, 2024 – CIS BIOPHARMA, a leading oncology-focused biotechnology firm, participated in the largest German-speaking congress in Oncology, hosted by the German, Austrian, and Swiss Societies for Hematology and Medical Oncology in Basel.

The company’s drug development team, comprising key personnel from research and development, attended the four-day conference to gain valuable insights into the latest clinical oncology trends. Their participation highlights the firm’s dedication to bridging the gap between laboratory research and clinical applications.

Michael Hackebeil, senior scientist remarked: «The conference provided a fascinating perspective on the translational aspects of our laboratory work, particularly in the realm of Antibody Drug Conjugates (ADCs) and other innovative therapies.»

Franziska Strütt, member of the drug development team, emphasized the educational value of the event, stating: «The proximity of such high-level expert discussions to our Basel headquarters is invaluable for our ongoing research efforts.»

Daniela Winkler, the team’s head of synthesis, concluded: «The insights gained from this conference will directly enhance our R&D pipeline, ensuring that our innovation  continues to address the most pressing needs in oncology.»

This engagement demonstrates the company’s proactive approach to integrating cutting-edge clinical knowledge into its research and development processes.

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs,  that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.